ClinConnect ClinConnect Logo
Search / Trial NCT06936904

Different Injection Speed on Local Anaesthetic Spread of ESPB

Launched by NANJING FIRST HOSPITAL, NANJING MEDICAL UNIVERSITY · Apr 13, 2025

Trial Information

Current as of July 23, 2025

Recruiting

Keywords

ClinConnect Summary

This clinical trial is looking at how the speed of injecting local anesthetic affects its spread in a procedure called the erector spinae plane block (ESPB). This block is used to numb an area during a procedure for lung nodules. The researchers want to find out if injecting the anesthetic quickly (in 30 seconds) makes it work differently compared to a slower injection (in 180 seconds).

To be eligible for this trial, participants need to be between 18 and 80 years old, scheduled for a CT-guided lung nodule localization, and have a body mass index (BMI) between 18 and 30. They must also be healthy enough for the procedure, with certain medical classifications. However, people with allergies to the anesthetic, a history of opioid abuse, or specific medical conditions may not qualify. If you join the trial, you can expect to help researchers learn more about the best way to deliver anesthesia to improve patient care during these types of procedures.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Patients scheduled for CT-guided lung nodule localization under local anesthesia will be selected
  • 1. aged 18-80 years
  • 2. BMI 18-30 kg/m²
  • 3. ASA classification I-III
  • Exclusion Criteria:
  • 1. Allergy to the study drug or to local anesthetics
  • 2. History of opioid abuse
  • 3. Previous infection at the ESPB or PVB puncture site
  • 4. Peripheral neuropathy
  • 5. Dysfunction of blood coagulation

About Nanjing First Hospital, Nanjing Medical University

Nanjing First Hospital, affiliated with Nanjing Medical University, is a leading medical institution dedicated to advancing healthcare through innovative research and clinical trials. With a strong emphasis on patient-centered care and cutting-edge medical practices, the hospital serves as a key player in the development of new therapies and treatment protocols. Its collaborative environment fosters interdisciplinary research, enabling the integration of scientific inquiry with clinical application. Nanjing First Hospital is committed to improving health outcomes and contributing to the global medical community through rigorous trial design and execution, ensuring the highest standards of ethical practice and patient safety.

Locations

Nanjing, Jiangsu, China

Patients applied

0 patients applied

Trial Officials

Tao Shan

Study Chair

Nanjing First Hospital, Nanjing Medical University

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported